BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

The Day In Review: Allergan Inc. (AGN) Expands Obesity Franchise


2/23/2007 1:34:22 PM

February 22, 2007 -- Allergan paid $97 million for EndoArt, which produces remote-controlled implants for obesity and other conditions; Genentech fell under the double burden of two negative news stories; Advair from GlaxoSmithKline failed to meet its endpoint in a COPD trial; Hollis-Eden released positive data from pre-clinical tests of a prostate/breast cancer drug; Ikaria and INO Therapeutics were both absorbed into Ikaria Holdings in a deal worth $670 million; Emergent BioSolutions said the government cancelled its request for proposals to supply anthrax vaccines; GlaxoSmithKline has begun warning that rosiglitazone causes bone fractures in female patients; and Cell Genesys and Medarex reported encouraging results from immunotherapy GVAX. The Centient Biotech 200™ fell 31 points to 4054, a loss of .76%. More details...


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->